Skip to main content
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
FR
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
  • Find Reports
    • Programs & Initiatives
      • Aging in Place
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Emergency Department Overcrowding
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
FR
  • Find Reports
  • Our Work
    • Programs & Initiatives
      • Advisory Panel: Pan-Canadian Prescription Drug List
      • Aging in Place
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Emergency Department Overcrowding
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
  • Get Involved
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe

Efalizumab

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : October 25, 2005

Niacin/lovastatin

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : October 18, 2005

Insulin aspart/insulin aspart protamine

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : October 13, 2005

Tenofovir disoproxil fumarate

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : August 11, 2005

Abacavir/lamivudine

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : July 26, 2005

Erlotinib

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : July 19, 2005

Pregabalin

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : June 27, 2005

Mycophenolate sodium

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : March 3, 2005

Insulin glargine (rDNA origin)

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : February 11, 2005

Laronidase

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : February 3, 2005

Pagination

  • Previous page ‹‹
  • Page 108
  • Next page ››

Canada’s Drug Agency is a pan-Canadian health organization, created and funded by Canada’s federal, provincial, and territorial governments.

We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact. 

  • Reports
  • Contact
  • Careers
  • Help

Stay up to date on the latest from Canada’s Drug Agency by subscribing to our newsletter.

Already subscribed? Update your preferences.

  • visit us on facebook
  • visit us on linkedin
  • visit us on youtube
  • visit us on instagram

© 2025 Canadian Agency for Drugs and Technologies in Health

  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Request for Archived Report
Back to Top